Related Experiment Video
Updated: May 17, 2026

10:09
A Straightforward Method for Glucosinolate Extraction and Analysis with High-pressure Liquid Chromatography (HPLC)
Published on: March 15, 2017
Two new neolignan glucosides from Arctii Fructus
Ya-Nan Yang1, Fan Zhang, Zi-Ming Feng
1State Key Laboratory of Bioactive Substance and Function of Natural Medicines, Peking Union Medical College and Institute of Materia Medica, Chinese Academy of Medical Sciences, Beijing 100050, China.
Journal of Asian Natural Products Research
|October 11, 2012
Summary
Researchers isolated two novel neolignan glucosides and two small molecular peptides from Arctii Fructus extract. These compounds
Area of Science:
- Phytochemistry
- Natural Product Chemistry
Background:
- Arctii Fructus (Burdock fruit) is a traditional medicinal herb.
- Natural products research aims to discover novel bioactive compounds.
Purpose of the Study:
- To isolate and characterize new chemical constituents from Arctii Fructus.
- To elucidate the structures and absolute configurations of these compounds.
Main Methods:
- Extraction from Arctii Fructus.
- Isolation of compounds using chromatographic techniques.
- Structure elucidation via spectroscopic methods including IR, HR-ESI-MS, 1D and 2D NMR, and CD analysis.
Main Results:
- Two new neolignan glucosides were identified: (7S, 8R)-4,7,9,9'-tetrahydroxy-3,3'-dimethoxyl-7'-oxo-8-4'-oxyneolignan-4-O-β-D-glucopyranoside and (7'S, 8'R, 8S)-4,4',9'-trihydroxy-3,3'-dimethoxy-7',9-epoxylignan-7-oxo-4-O-β-D-glucopyranosyl-4'-O-β-D-glucopyranoside.
- Two known small molecular peptides, 3-benzyl-6-(1-hydroxyethyl)-2,5-piperazinedione and 3-benzyl-2,5-piperazinedione, were also isolated.
- The structures and absolute configurations were confirmed through comprehensive spectroscopic analysis.
Conclusions:
- The study successfully identified and characterized four compounds from Arctii Fructus, including two novel neolignan glucosides.
- The findings contribute to the understanding of the chemical diversity of Arctii Fructus.
- These isolated compounds may serve as leads for further pharmacological investigations.
Related Concept Videos
Glucagon-like Receptor Agonists
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are typically...
Acarbose and miglitol are typically...
